IFNG and non-small cell lung carcinoma: Every process, however, also offers therapeutic potential: hypoxia-toxic drugs to enhance antigen visibility, IFN-γ or demethylating agents to rescue EMT-mediated loss, STAT3 inhibition in acidic tumors, and β5i-patient selection in NSCLC.